Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 110 results for melanoma

  1. Survivorship: What are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease journey?

    are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease...

    Research recommendation
    Published
    4 August 2022

  2. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

    Clinical guideline
    Last updated
    1 September 2017
    View recommendations

    Sections for CG153

  3. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

    Technology appraisal guidance
    In development

  4. Surveillance strategies: How frequently should surveillance imaging be conducted, and which imaging modality should be used for people with stage IIB to IIIC melanoma?

    which imaging modality should be used for people with stage IIB to IIIC melanoma? Any explanatory notes(if applicable) For a short...

    Research recommendation
    Published
    4 August 2022

  5. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. NICE considered that more research is needed to establish the treatment sequence for vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma.

    vemurafenib and ipilimumab in patients who have BRAF V600 mutation-positive melanoma. Any explanatory notes(if applicable) This may...

    Research recommendation
    Published
    9 June 2015

  7. Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve overall survival? This should be investigated in a placebo controlled randomised trial. Secondary outcomes should include disease specific survival and toxicity, including the development of renal stones and hypercalcaemia.

    Question Vitamin D supplementation: In people with stage I to III melanoma does vitamin D supplementation improve overall survival? This...

    Research recommendation
    Published
    4 August 2022

  8. Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

    Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    26 April 2017
    View recommendations

    Sections for TA442

  9. Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)

    This guideline covers assessing and managing cancers of the upper aerodigestive tract in people aged 16 or over. These are cancers of the airways of the head and neck, including the mouth, throat, larynx (voicebox) and sinuses. The guideline aims to reduce variation in practice and improve survival.

    NICE guideline
    Last updated
    6 June 2018
    View recommendations

    Sections for NG36

  10. Endoscopic radical inguinal lymphadenectomy (HTG265)

    Evidence-based recommendations on endoscopic radical inguinal lymphadenectomy. This involves using an endoscopic device and small incisions to reduce discomfort, scarring and complications associated with inguinal lymph node removal.

    HealthTech guidance
    Published
    22 June 2011
    View recommendations

    Sections for HTG265

  11. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (HTG717)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

    HealthTech guidance
    Published
    16 April 2024
    View recommendations

    Sections for HTG717

  12. Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)

    Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.

    Technology appraisal guidance
    Published
    28 May 2025

    Sections for TA1065

  13. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

    Interventional procedures guidance
    Discontinued

  14. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development Reference number: GID-TA11458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Interstitial photodynamic therapy for malignant parotid tumours (HTG166)

    Evidence-based recommendations on interstitial photodynamic therapy for malignant parotid tumours. This involves injecting a photosensitising agent into a vein and using a special light to activate it and destroy the tumour cells.

    HealthTech guidance
    Published
    23 April 2008
    View recommendations

    Sections for HTG166